Results 171 to 180 of about 840,804 (341)

Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity

open access: gold, 2021
Begoña Navarro-Almenzar   +2 more
openalex   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi   +3 more
wiley   +1 more source

Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Inflammation is postulated to be a key pathogenic mechanism in heart failure with preserved ejection fraction (HFpEF). Soluble urokinase plasminogen activator receptor (suPAR), a regulator of innate immune activity, is associated with incident heart failure; however, its role in HFpEF remains unclear.
Christina G. Hutten   +9 more
wiley   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

open access: yesHepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah   +2 more
wiley   +1 more source

Increased Soluble Leptin Receptor Levels in Morbidly Obese Patients With Insulin Resistance and Nonalcoholic Fatty Liver Disease [PDF]

open access: bronze, 2010
Valentina Medici   +14 more
openalex   +1 more source

Elastic Power of Mechanical Ventilation in Morbid Obesity and Severe Hypoxemia [PDF]

open access: bronze, 2020
Muhammad K. Hayat Syed   +4 more
openalex   +1 more source

Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients

open access: yesAntimicrobial Agents and Chemotherapy, 2017
A. Alobaid   +11 more
semanticscholar   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

open access: yesESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp   +9 more
wiley   +1 more source

Macrophage‐derived MLKL in alcohol‐associated liver disease: Regulation of phagocytosis

open access: yesHepatology, EarlyView., 2022
EtOH causes leaky gut allowing bacteria and PAMPs into the liver, resulting in hepatic inflammation and injury. We demonstrate that LPS induces STAT1‐mediated expression and phosphorylation of MLKL in macrophages and identify a novel function that myeloid MLKL translocates to phagosomes and lysosomes and regulates phagocytosis, which contributes to the
Xiaoqin Wu   +16 more
wiley   +1 more source

Voxel-Mirrored Homotopic Connectivity Is Altered in Meibomian Gland Dysfunction Patients That Are Morbidly Obese [PDF]

open access: gold, 2022
Yi-Dan Shi   +10 more
openalex   +1 more source

Home - About - Disclaimer - Privacy